Pipeline

Cezanne-1 Program

Cezanne-1: a DUB disease target for inflammation

Lead optimization program

Therapeutic rationale

The pathology of inflammatory diseases such as psoriasis, rheumatoid arthritis and multiple sclerosis is driven by several pro-inflammatory cytokines, including IL-17A, IL-17F, IL-21, TNF and interferon, which are produced by specific T helper cells (Th17/Th1). Mission has identified potent and selective small molecule inhibitors against the de-ubiquitylating enzyme Cezanne-1, which demonstrate strong inhibition of Th17/Th1 cells.

Inhibition of Cezanne-1 potentially represents a novel first-in-class small molecule approach for specifically targeting inflammatory disease.